Specialty Pharmaceutical Organization Awards $1 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Informati

Specialty Pharmaceutical Organization Awards $1 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information Distribution
Services
Thorough Phase I ECG Study Identified as Key to Approval 


PHILADELPHIA, June 3  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT)
(NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has been
awarded approximately $1 million in cardiac safety monitoring and services from
a specialty pharmaceutical organization for one of its drug candidates in
clinical development.

The award covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.  The study is
targeted for completion over a 90-day period.

"We are delighted to have been awarded this important study, which provides us
the ability to support this rapidly emerging specialty pharmaceutical
organization in a key commercialization initiative," said Scott Grisanti,
senior vice president of business development and chief marketing officer at
eRT.  "eRT's extensive Thorough Phase I ECG Study experience, combined with our
scientific consulting and Clinical Pharmacology Unit partnerships, enabled eRT
to rapidly coordinate delivery of a turnkey solution including study conduct,
ECG core laboratory services, scientific consulting and regulatory
representation."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  This award may be canceled by the sponsor at its sole discretion.  As
a result, actual results may differ materially from any financial outlooks
stated herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright